Promiscuous Ligands from Experimentally Determined Structures, Binding Conformations, and Protein Family-Dependent Interaction Hotspots
暂无分享,去创建一个
[1] M. Rosini,et al. Polypharmacology: the rise of multitarget drugs over combination therapies. , 2014, Future medicinal chemistry.
[2] Fatemeh Atyabi,et al. Fluorescence properties of several chemotherapy drugs: doxorubicin, paclitaxel and bleomycin. , 2016, Biomedical optics express.
[3] Jürgen Bajorath,et al. How Frequently Are Pan-Assay Interference Compounds Active? Large-Scale Analysis of Screening Data Reveals Diverse Activity Profiles, Low Global Hit Frequency, and Many Consistently Inactive Compounds. , 2017, Journal of medicinal chemistry.
[4] T. N. Bhat,et al. The Protein Data Bank , 2000, Nucleic Acids Res..
[5] K. Morikawa,et al. The nuclear receptor PPARγ individually responds to serotonin‐ and fatty acid‐metabolites , 2010, The EMBO journal.
[6] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[7] Zukang Feng,et al. Ligand Depot: a data warehouse for ligands bound to macromolecules , 2004, Bioinform..
[8] P. Bork,et al. Systematic identification of proteins that elicit drug side effects , 2013, Molecular systems biology.
[9] Ping Chen,et al. Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance , 2016, Molecular Cancer Therapeutics.
[10] J. Bajorath,et al. Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.
[11] Mineyuki Mizuguchi,et al. Structural Insight into the Interactions between Death-Associated Protein Kinase 1 and Natural Flavonoids. , 2015, Journal of medicinal chemistry.
[12] K. Merz,et al. The Ecstasy and Agony of Assay Interference Compounds , 2017, J. Chem. Inf. Model..
[13] Alexander Tropsha,et al. Phantom PAINS: Problems with the Utility of Alerts for Pan-Assay INterference CompoundS , 2017, J. Chem. Inf. Model..
[14] A. Pîrnău,et al. Binding interaction of indomethacin with human serum albumin. , 2008, Journal of pharmaceutical and biomedical analysis.
[15] Jürgen Bajorath,et al. Highly Promiscuous Small Molecules from Biological Screening Assays Include Many Pan-Assay Interference Compounds but Also Candidates for Polypharmacology. , 2016, Journal of medicinal chemistry.
[16] J. Bajorath,et al. X-ray Structures of Target-Ligand Complexes Containing Compounds with Assay Interference Potential. , 2018, Journal of medicinal chemistry.
[17] B. Shoichet. Screening in a spirit haunted world. , 2006, Drug discovery today.
[18] John P. Overington,et al. Structural and Functional View of Polypharmacology , 2016, bioRxiv.
[19] L. Williams,et al. Surprising roles of electrostatic interactions in DNA-ligand complexes. , 2003, Biopolymers.
[20] A. Cavalli,et al. Multitarget Drug Discovery and Polypharmacology , 2016, ChemMedChem.
[21] W. Atkins,et al. A quantitative index of substrate promiscuity. , 2008, Biochemistry.
[22] Jürgen Bajorath,et al. Systematic mining of analog series with related core structures in multi-target activity space , 2013, Journal of Computer-Aided Molecular Design.
[23] Mahesh Hegde,et al. Quercetin, a Natural Flavonoid Interacts with DNA, Arrests Cell Cycle and Causes Tumor Regression by Activating Mitochondrial Pathway of Apoptosis , 2016, Scientific Reports.
[24] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[25] J. Skolnick,et al. Catalytic and substrate promiscuity: distinct multiple chemistries catalysed by the phosphatase domain of receptor protein tyrosine phosphatase. , 2016, The Biochemical journal.
[26] Dusanka Janezic,et al. ProBiS-Database: Precalculated Binding Site Similarities and Local Pairwise Alignments of PDB Structures , 2012, J. Chem. Inf. Model..
[27] S. Olesen,et al. Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors , 2014, ACS chemical biology.
[28] Renxiao Wang,et al. Analysis of Ligand-Bound Water Molecules in High-Resolution Crystal Structures of Protein-Ligand Complexes , 2007, J. Chem. Inf. Model..
[29] Fernanda Borges,et al. Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances. , 2017, Journal of medicinal chemistry.
[30] Jürgen Bajorath,et al. Computational Method for the Systematic Identification of Analog Series and Key Compounds Representing Series and Their Biological Activity Profiles. , 2016, Journal of medicinal chemistry.
[31] G. Lucas,et al. Drug Interactions and Antiretroviral Drug Monitoring , 2014, Current HIV/AIDS Reports.
[32] F. Blanco,et al. Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. , 1999, The Journal of rheumatology.
[33] Sujata Sharma,et al. Simultaneous inhibition of anti‐coagulation and inflammation: crystal structure of phospholipase A2 complexed with indomethacin at 1.4 Å resolution reveals the presence of the new common ligand‐binding site , 2009, Journal of molecular recognition : JMR.
[34] P. Dorrestein,et al. Phenotyping drug polypharmacology via eicosanoid profiling of blood[S] , 2015, Journal of Lipid Research.
[35] Alex M. Clark,et al. 2D Depiction of Protein-Ligand Complexes , 2007, J. Chem. Inf. Model..
[36] J. Lehár,et al. Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.
[37] K. Diederichs,et al. Transport of drugs by the multidrug transporter AcrB involves an access and a deep binding pocket that are separated by a switch-loop , 2012, Proceedings of the National Academy of Sciences.
[38] Xu Wang,et al. A structural mechanism of flavonoids in inhibiting serine proteases. , 2017, Food & function.
[39] M L Bolognesi,et al. Polypharmacology in a single drug: multitarget drugs. , 2013, Current medicinal chemistry.
[40] Jürgen Bajorath,et al. Design of a Three-Dimensional Multitarget Activity Landscape , 2012, J. Chem. Inf. Model..
[41] John P. Overington,et al. Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.
[42] Cathy H. Wu,et al. UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..
[43] Renxiao Wang,et al. The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. , 2004, Journal of medicinal chemistry.
[44] J. Baell,et al. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.
[45] J Willem M Nissink,et al. Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017—Utility and Limitations , 2017, ACS chemical biology.
[46] B. Shilton,et al. Binding of DNA-Intercalating Agents to Oxidized and Reduced Quinone Reductase 2. , 2015, Biochemistry.
[47] B. Shoichet,et al. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.
[48] L. Wienkers,et al. Characterization of Ritonavir-Mediated Inactivation of Cytochrome P450 3A4 , 2014, Molecular Pharmacology.
[49] K. Shokat,et al. Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.
[50] S. Fetzner,et al. Quercetin 2,4-Dioxygenase Activates Dioxygen in a Side-On O2-Ni Complex. , 2016, Angewandte Chemie.
[51] J. Bajorath,et al. Compound promiscuity: what can we learn from current data? , 2013, Drug discovery today.
[52] Jürgen Bajorath,et al. SAR Matrix Method for Large-Scale Analysis of Compound Structure-Activity Relationships and Exploration of Multitarget Activity Spaces. , 2018, Methods in molecular biology.
[53] R. Morphy,et al. Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.
[54] John J. Irwin,et al. ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..
[55] Jürgen Bajorath,et al. X-ray-Structure-Based Identification of Compounds with Activity against Targets from Different Families and Generation of Templates for Multitarget Ligand Design , 2018, ACS omega.
[56] B. Cronstein,et al. Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis , 2005, Pharmacological Reviews.
[57] A. Hopkins. Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.
[58] J. Baell,et al. Chemistry: Chemical con artists foil drug discovery , 2014, Nature.
[59] B. Giardina,et al. New developments in anthracycline-induced cardiotoxicity. , 2009, Current medicinal chemistry.
[60] Michael Schroeder,et al. Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key , 2013, PloS one.